April 13, 2024

Structure-Guided Discovery and Preclinical Assessment of Novel (Thiophen-3-yl)aminopyrimidine Derivatives as Potent ERK1/2 Inhibitors

Key Points

Key points are not available for this paper at this time.

Abstract

The RAS-RAF-MEK-ERK signaling cascade is abnormally activated in various tumors, playing a crucial role in mediating tumor progression. As the key component at the terminal stage of this cascade, ERK1/2 emerges as a potential antitumor target and offers a promising therapeutic strategy for tumors harboring BRAF or RAS mutations. Here, we identified

Demander à l'IA

Bookmark

Cite This Study

Wen et al. (Sat,) studied this question.

synapsesocial.com/papers/68e6f4bdb6db64358766f483 https://doi.org/https://doi.org/10.1021/acs.jmedchem.3c02392

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Therapeutic regulation of autophagy in hepatic metabolism2021 · 135 citations
2Structure-Guided Design of Potent and Selective Pyrimidylpyrrole Inhibitors of Extracellular Signal-Regulated Kinase (ERK) Using Conformational Control2009 · 145 citations
3Membrane Bound Peroxiredoxin-1 Serves as a Biomarker for <i>In Vivo</i> Detection of Sessile Serrated Adenomas2021 · 8 citations
4Flavopiridol Synergizes with Sorafenib to Induce Cytotoxicity and Potentiate Antitumorigenic Activity in EGFR/HER-2 and Mutant RAS/RAF Breast Cancer Model Systems2013 · 39 citations
5Targeting Aberrant RAS/RAF/MEK/ERK Signaling for Cancer Therapy2020 · 539 citations

Demander à l'IA

Bookmark